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Background: Tendon injuries are very common in horses and jeopardize the athletic
performance, and due to the high risk of reinjury may lead to early retirement. The
use of mesenchymal stem cells for the treatment of equine tendon disease is widely
investigated because of their regenerative potential. The objective of this study is to
investigate the safety and efficacy of equine allogeneic tenogenic primed mesenchymal
stem cells (tpMSCs) for the management of tendinitis in horses.
Methods: A core lesion was surgically induced in the superficial digital flexor tendon
of both forelimbs of eight horses. After 7 days, one forelimb was treated with tpMSCs,
while the contralateral forelimb served as an intra-individual control and was treated with
saline. A prescribed exercise program was started. All horses underwent a daily clinical
evaluation throughout the entire study period of 112 days. Blood samples were taken
at different time points for hematological and biochemical analysis. Tendon assessment,
lameness examination, ultrasound assessment and ultrasound tissue characterization
(UTC) were performed at regular time intervals. At the end of the study period, the
superficial digital flexor tendons were evaluated macroscopically and histologically.
Results: No suspected or serious adverse events occurred during the entire study
period. There was no difference in local effects including heat and pain to pressure
between a single intralesional injection of allogeneic tpMSCs and a single intralesional
injection with saline. A transient moderate local swelling was noted in the tpMSC treated
limbs, which dissipated by day 11. Starting at a different time point depending on
the parameter, a significant improvement was observed in the tpMSC treated limbs
compared to the placebo for echogenicity score, fiber alignment score, anterior-posterior
thickness of the tendon and echo type by UTC assessment. Immunohistochemistry 112
days post-injection revealed that the amount of collagen type I and Von Willebrand factor
Depuydt et al. tpMSC Treatment for Tendon Injuries
were significantly higher in the tendon tissue of the tpMSC group, while the amount of
collagen type III and smooth muscle actin was significantly lower.
Conclusion: Equine allogeneic tenogenic primed mesenchymal stem cells were shown
to be well-tolerated and may be effective for the management of tendon injuries.
Keywords: mesenchymal stem cells, allogeneic, tenogenic primed, SDFT, peripheral blood, horse
INTRODUCTION
Tendon injuries are very common in both human (1, 2) and
equine athletes (3, 4), and often result in reinjury or early
retirement (5). In racehorses, tendon and ligament injuries are
the most common orthopedic diseases (6–8), but also dressage,
eventing, show jumping, and pleasure riding horses suffer from
tendon pathologies (9, 10). The formation of scar tissue as a
sequel to tendon injury hampers the natural healing process and
subsequently impairs the normal tendon function (11).
Healthy tendon tissue is mainly composed of type I collagen,
contributing to a remarkable tensile strength and elasticity.
In case of an acute tendon trauma, an inflammatory phase
is initiated that is characterized by the formation of a local
hematoma and induction of an inflammatory reaction at the site
of the tendon tear or lesion (12). Around 7 days after the injury,
the proliferative phase develops, which includes angiogenesis and
fibroplasia with random depositions of collagen type III (13). The
smaller and less organized fibrils of collagen type III result in
loss of original tensile strength and elasticity (13, 14). Finally,
6–8 weeks after injury, the remodeling phase sets in, which is
characterized by a decrease in type III collagen and an increase
in synthesis of collagen type I. However, the repair tissue never
reaches the tensile characteristics of healthy tendon, resulting in
the formation of rigid scar tissue with increased risk of tendon
reinjury (12, 15). Despite major progress in the early detection
of tendon injuries and the development of advanced therapies,
the healing process is slow with an inferior quality of the
repaired tendon tissue (5). Therefore, there is a need for further
research on treatments aiming to restore tendon functionality,
encouraging the development of regenerative treatments such as
cell-based therapies.
Recently, promising advances have been made in the
treatment of equine tendon injuries in the field of mesenchymal
stem cell (MSC) therapy. Naturally occurring superficial digital
flexor tendinopathy treated with MSCs resulted in a reduced
reinjury rate and better tendon echogenicity (5, 16–19).
Additionally, experimental studies using MSCs as treatment for
surgically or enzymatically induced tendon core lesions report
Abbreviations: AAEP, American association of equine practitioners; APT,
Anterior-posterior thickness; AT-MSC(s), Adipose tissue-derived mesenchymal
stem cell(s); BM-MSC(s), Bone marrow-derived mesenchymal stem cell(s); COL
I, Collagen type I; COL III, Collagen type III; CP, Control product; DAB,
Diaminobenzidine; EDTA, Ethylenediaminetetraacetic acid; HRP, Horseradish
peroxidase; IVP, Investigational product; MSC(s), Mesenchymal stem cell(s);
PBS, Phosphate buffered saline; PRP, Platelet rich plasma; SDFT, Superficial
digital flexor tendon; SMA, Smooth muscle actin; tpMSC(s), Tenogenic primed
mesenchymal stem cell(s); UTC, Ultrasound tissue characterization; VWF, Von
Willebrand factor.
better tendon echogenicity and a higher collagen type I/collagen
type III ratio (20, 21). Although MSCs are a valuable option in
the treatment of tendon disease, their tenogenic properties and
regenerative effects could be compromised by the inflammatory
environment of the acute tendon injury (22). This was observed
in the study of Geburek et al. (23) where no significant reduction
in clinical signs of inflammation and no reduction of fluid
during ultrasonography could be detected following adipose
tissue-derived MSC (AT-MSC) injection in surgically induced
superficial digital flexor tendon (SDFT) core lesions. Although
not in horses, ectopic bone formation has been reported in
rabbits and mice after administration of bone marrow-derived
MSCs (BM-MSCs) into acute tendon lesions (14, 24–26). In
order to avoid these disadvantageous effects, MSCs can be
tenogenic primed before clinical application (27). Previous work
reported the safe use of equine allogeneic peripheral blood-
derived tenogenic primed MSCs (tpMSCs) in combination with
platelet rich plasma (PRP) and positive outcome in horses with
naturally occurring tendinopathies (28, 29). Broeckx et al. (28)
described the successful treatment of lesions in the suspensory
ligament and SDFT with tpMSCs in combination with PRP in
24 out of 25 horses based on ultrasonographic and lameness
evaluations 6 weeks post-treatment. Moreover, Beerts et al. (29)
reported that 85.7% of horses with a naturally occurring lesion
in the SDFT returned to their previous performance level after
treatment with tpMSCs in combination with PRP in a 2-year
follow-up study. These findings indicate that the use of tpMSCs
in combination with PRP is promising for future applications.
However, placebo-controlled, randomized and blinded studies
to objectively investigate the safety and efficacy of allogeneic
tpMSCs are currently lacking.
Therefore, the goal of this study was to assess the safety and
efficacy of a single intralesional injection of equine allogeneic
tenogenic primed MSCs in a surgical induced core lesion
model in the equine SDFT. In this research, the treatment
effect of tpMSCs was compared to a control product (saline)
evaluating tendon and lameness assessment, echogenicity and
fiber alignment scoring, ultrasonographic tissue characterization
and immunohistochemistry data.
MATERIALS AND METHODS
This animal study (EC_2017_001) including the blood collection
from the donor horses (EC_2016_003) was approved by
an independent ethics committee approved by the Flemish
government (permit number: LA1700607). The study was
conducted under GLP standards in accordance with national and
international animal welfare regulations (Directive 2001/82/EC
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as amended, Belgian animal welfare legislation (KB 29/05/2013),
Directive 2010/63/EU and EMEA/CVMP/816/00-Final).
Study Design and Horses
Eight healthy warmblood horses, four geldings and four mares
(age ranged between 3 and 12 years) were enrolled in this
blinded, placebo-controlled, randomized study. The horses were
free of lameness and swelling, heat or reaction to palpation
of the SDFT of both forelimbs at the time of enrollment. To
reduce the number of horses, this study compared the effect
of the investigational product (IVP) and the control product
(CP) within the same horse. Each of the horses received the
CP in one of its forelimbs and the IVP in its contralateral
forelimb. The treatment allocation was randomized. Thus, one
forelimb within a horse was randomly allocated to the IVP
group (n = 8), while the contralateral limb was assigned to the
CP group (n = 8). All clinical, tendon, lameness, ultrasound,
and histopathological parameters were evaluated by an examiner
blinded to the treatment.
Investigational Product and Control
Product
The IVP consisted of a proprietary formulation of equine
allogeneic tenogenic primed mesenchymal stem cells (tpMSCs)
prepared from peripheral blood as previously described (28).
Briefly, blood was collected aseptically from the vena jugularis
in sterile ethylenediaminetetraacetic acid (EDTA) tubes. After
gradient centrifugation, the interphase was isolated, seeded and
cultivated in culture medium as previously described (30). At
80% confluency, the cells were trypsinized and cultured in
tenogenic primingmedium. At the next confluency, the cells were
trypsinized and resuspended in 1mL Dulbecco’s modified Eagle
medium low glucose supplemented with 10% dimethyl sulfoxide.
The samples were cryopreserved at −80◦C until further use. In
the present study, two different tpMSC batches of the same donor
horse that were produced on two different time points were used.
Each forelimb within one horse was randomly allocated either to
one of the two batches. The donor horse was screened for equine
pathogens as previously reported by our group (28).
The control product consisted of 1mL sterile saline injectable
solution (0.9% NaCl).
Surgical Procedure and Post-operative
Treatment
One week before treatment administration [day-7: reported
time point that fibroblast ingrowth starts (13)], a standardized
lesion in the SDFT of both forelimbs was created using a
surgical model adapted from Schramme et al. (31) and Bosch
et al. (32, 33) (Table 1). The surgery was performed under
general anesthesia and followed routine clinical procedures.
Pre-operatively, horses were sedated using romifidine (0.8
mL/100 kg body weight; Sedivet R©, intravenous). General
anesthesia was induced using ketamine (2.2 mL/100 kg body
weight; Ketamidor R©, intravenous) and midazolam (0.1 mg/kg
body weight; Midazolam Mylan, intravenous). Anesthesia was
maintained during the surgical procedure by administration of
isoflurane (IsoFlo R© MAC∗ = 1.3%) under controlled ventilation.
The horses were positioned in right lateral recumbency. After
circumferential clipping and aseptical preparation of the surgical
sites, a small skin incision (1 cm) was made in the palmar midline
of the limbs just proximal to the digital flexor tendon sheath.
Through a small longitudinal incision into the SDFT (1 cm),
a 3.5mm Steinmann pin was inserted in the core of the SDFT
under ultrasonographic guidance and a central lesion over an
area of 8 cm was created. Next, an arthroscopic burr (∅ 3.5mm
Razorcut blade; C9110; Linvatec, Largo, Florida, USA) was
inserted in the defect created by the Steinmann pin and was
advanced proximally over a length of 8 cm. After activation, the
burr was slowly retracted over 1min while performing a rotating
movement making sure that the medial, palmar and lateral
aspect of the tendon was debrided. Local pressure on the SDFT
was exerted to assist in this debridement. The shaver was used
in forward modus at 5,000 rpm. No suction was applied. The
incisions in the paratenon and skin were sutured using simple
interrupted sutures with resorbable polyglyconate (Monosyn
USP 3-0 B. Braun).
A bandage was applied to the limbs for 7 days after surgery,
until treatment administration. A new bandage was placed
after treatment (day 0). The bandage was removed for tendon
assessment on day 1–3 after treatment and replaced after the
assessment. From day 4 to 7 after treatment, the bandage was
removed at 10 a.m. ± 1 h and replaced at 4 p.m. ± 1 h right after
tendon assessment. One week after surgery, the sutures and the
bandage were removed permanently.
Horses were walked for 6 days after surgery using a horse
walker (Table 2) and received an intralesional tpMSC or placebo
treatment at 7 days post-surgery as described below. A gradually
increasing exercise protocol was started from day 4 after
treatment onwards using a horse walker (Table 2). Care was
taken to exercise in both directions equally.
Treatment Administration
At day 0, one week post-surgery, the horses were mildly sedated
with detomidine hydrochloride (0.1 mL/100 kg body weight,
Detogesic R©, intravenous). The area around the injection site
was clipped and aseptically prepared. The tendon was punctured
laterally and the treatments (IVP and CP) were administered by
a single intralesional injection in the SDFT core lesion under
ultrasonographic guidance to ensure a successful administration
to the site of the lesion. For the IVP, the tpMSCs were thawed
in the palm of a hand and drawn into a syringe. Both IVP and
CP treatments were administered by an assigned veterinarian
(the dispenser), who did not participate in any of the clinical
or laboratory examinations. This way blinding of the personnel
who assessed the efficacy and safety parameters and performed
the post-mortem evaluation was ensured.
Clinical Assessment
A general clinical examination of the horses was conducted and
recorded daily throughout the study (from day −10 until day
112 ± 1). The body temperature, heart and respiratory rates,
mucous membrane color, capillary refill time, and feed intake
were evaluated. The body weight of the horses was recorded on
day−10 and 112± 1.
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TABLE 1 | Comparison of surgically induced SDFT core lesions in the current













3.5mm 3.5mm 3.5 mm
Lesion length 8 cm 8cm 7 cm



















Follow-up 16 weeks 2, 4, 8, and 12
weeks
24 weeks
During the study period from the day of treatment
administration (day 0) to study completion, all horses were
observed daily for adverse events, serious adverse events and
suspected adverse drug reactions and these were recorded
when occurring.
Blood Sample Collection and Analysis
Blood was collected from the vena jugularis into EDTA tubes and
serum clot activator tubes for analysis of following hematological
and biochemical blood parameters in an ISO15189 certified
laboratory (Vebio, France): white blood cell count, red blood
cell count, hemoglobin, hematocrit, mean corpuscular volume,
mean corpuscular hemoglobin, mean corpuscular hemoglobin
concentration, neutrophils, eosinophils, lymphocytes, platelet
count, basophils, monocytes, reticulocytes, blood urea nitrogen,
urea, creatinine, total protein, albumin, globulin, alkaline
phosphatase, serum glutamic oxaloacetic transaminase, total and
direct bilirubin, creatinine kinase, lactic dehydrogenase, and
gamma-glutamyl transpeptidase.
Tendon Assessment
The tendon assessment was performed on following days: −9
(before surgical procedure), 0 (before treatment), daily on days
1–14, 28, 42, 56, 84, and 112 ± 1. Both forelimbs of each horse
were evaluated at each time point. A score was given to the
local heat, pain to pressure, and the swelling (Table 3). Also, the
circumference measurement (cm) of each forelimb was recorded
using a measuring tape. The tape was placed at the level of the
metacarpus just proximal to the digital flexor tendon sheath with
the limb in a weight bearing position. All measurements were
performed on both forelimbs and the values at each time point
were compared to the baseline values (day−9 and day 0).
TABLE 2 | Exercise protocol of the horses after bilateral surgical induction of a
SDFT core lesion.
Time point ′W = minutes walking, once per day
′T = minutes trotting, once per day
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This exercise scheme was performed once a day. Care was taken to exercise equally in




TABLE 3 | Clinical scores used in all horses to assess local heat, swelling, and
pain to pressure.
Parameter Score system Definition
Heat 0 No increased temperature sensation
1 Slightly increased temperature sensation
2 Moderately increased temperature sensation
3 Severely increased temperature sensation
Pain to pressure 0 No pain to pressure
1 Slight pain to pressure
2 Moderate pain to pressure
3 Severe pain to pressure





Lameness was assessed on following days:−9 (before the surgical
procedure), 0 (before treatment), 14, 56, and 112 ± 1 according
to the American Association of Equine Practitioners (AAEP)
scoring system (Table 4). The examining vet also evaluated
whether the lameness was attributed to the left or right front
limb or if the lameness was considered bilateral. The horses were
examined by walking and trotting in hand, on a straight line
and with a loose line to the halter. Evaluation in a circle was
performed during the revalidation exercise in the horse walker
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TABLE 4 | AAEP scoring.
Grade Degree of lameness
0 Lameness not perceptible under any circumstances
1 Lameness is difficult to observe and is not consistently apparent,
regardless of circumstances
2 Lameness is difficult to observe when walking or trotting in a
straight line, but consistently apparent under certain
circumstances
3 Lameness is consistently observable at a trot under all
circumstances
4 Lameness is obvious at walk
5 Lameness produces minimal weight bearing in motion and/or at
rest or a complete inability to move
TABLE 5 | Echo types and corresponding colors that were discriminated and
determined throughout the study (34).
Echo type (color code)Echo source according to histology
Echo type I (green) Echo generated by intact and fully aligned fiber bundles
Echo type II (blue) Echo generated by discontinuous and less aligned fiber
bundles
Echo type III (red) Echo generated by a mainly fibrillar matrix with
accumulation of collagen fibrils not (yet) organized into
fiber bundles
Echo type IV (black) Echo generated by an amorphous matrix and/or fluid
TABLE 6 | Ultrasound assessment.
Parameter Score system Definition






0 ≥75% parallel fiber bundles in the lesion
1 50–74% parallel fiber bundles in the
lesion
2 25–49% parallel fiber bundles in the
lesion
3 ≤25% parallel fiber bundles in the lesion
on a soft surface, and on a lunge. A firm, non-slippery surface
was used for trotting on a straight line and for lunging.
Ultrasound Tissue Characterization
The structural integrity of the SDFT of both forelimbs of
each horse was qualified using established protocols for an
ultrasound tissue source characterization (UTC) (32, 34). The
UTC assessment was performed on the following days: −9
(before surgery), 0 (before treatment), 14, 28, 42, 84, and 112± 1.
The horses were mildly sedated with detomidine hydrochloride
(0.1 cc/100 kg body weight, Detogesic R©, intravenous) and both
forelimbs were clipped, shaved and washed at the palmar aspect
of the metacarpus prior to each scan. Coupling gel was applied
to ensure maximum contact. For the UTC examination, a
12-5 MHz multi-frequency ultrasound probe (12 L5; Terason
Ultrasound, Teratech Corporation, Burlington, MA, USA)
connected to a laptop computer (MacBook Pro R© 17 inch, Apple,
Cupertine, CA, USA) loaded with software for data acquisition
and analysis (UTCTM Software V.1.0.1 2010, UTC Imaging,
Stein, The Netherlands) was used. The probe was fixed in a
motorized tracking device with built-in standoff pad (UTC-
TrackerTM; UTC Imaging). Settings (depth, gain, focal zone)
were standardized and all examinations were performed by the
same operator with the horse in weight bearing position, equally
on both forelimbs. With the help of the tracking device, the probe
moved automatically from proximal to distal parallel to the long
axis of the tendon at constant speed over a distance of 12 cm.
Compilation of contiguous transverse images was conducted at
precise steps of 0.2mm, including the insertion point of the
arthroscopic burr (scar in the epitenon) as the reference point
for the analysis. A clear ultrasound image of the SDFT was
obtained and checked to ensure no artifacts were present due
to movement or poor contact. The compiled 600 transverse
ultrasound images were reconstructed into a three-dimensional
data block of ultrasound information and stored digitally until
the end of the examination period. The stability of the echo
pattern of corresponding pixels in contiguous transverse images
can be analyzed (UTC2011 R© Analyser V1.0.1; UTC Imaging;
window size 17). Four different pixel types were classified based
on their stability and degree of persistence, resulting in four echo
types related to stages of ultrastructural integrity (Table 5) (34).
In the analysis, a 4 cm long tendon segment from 2 to 6 cm
proximal to the scar in the epitenon was selected. In this selected
segment, the percentage of echo types generated by the tendon
structure was evaluated.
Ultrasound Assessment
The ultrasound images obtained with the UTC device were used
for the ultrasound assessment. During this evaluation, three
different parameters were evaluated. First, the echogenicity of
each lesion was graded according to a pre-defined scoring system
(Table 6). Second, the fiber alignment was graded according to
the estimated percentage of parallel fiber bundles in the lesion
(Table 6). Third, an increase in anterior-posterior thickness
(APT) in cm was recorded to monitor tendon repair.
Histological Sampling Procedure
At day 112 ± 1 of the study, the horses were humanely
euthanized after sedation with romifidine (0.8 mL/100 kg body
weight; Sedivet R©) using ketamine (2.2 mL/100 kg body weight;
Ketamidor R©), midazolam (0.1 mg/kg body weight; Midazolam
Mylan) and T61 (0.3 mL/kg body weight; Hoechst Roussell Vet,
Frankfurt, Germany).
Immediately after euthanasia, the SDFT and paratenon of
both forelimbs of each horse were collected. After closing the
surgical wound the skin remained slightly raised, leaving the
original entry point of the arthroscopic burr visible throughout
the entire study period. This remaining scar could be used as a
reference for the entry point of the burr. The tendon segment
located 12 cm proximal to the entrance of the burr was obtained.
Next, transversal and longitudinal tendon sections were excised,
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and a macroscopic evaluation of these sections was performed.
Finally, digital photographs were taken from each tendon before
fixation in 10% natural-buffered formalin.
Samples of the cubital lymph nodes, prescapular lymph
nodes, spleen, liver, brain, kidneys, adrenal glands, lungs, heart
(ventricles and septum), stomach, duodenum, jejunum, ileum,
colon, and cecum were fixed in 10% natural-buffered formalin
for further histologic evaluation.
Macroscopic and Histopathologic
Examination
A macroscopic evaluation of tendon, paratenon, and cubital
lymph nodes of both forelimbs of each horse was performed.
The lesion and color of the tendon were observed and
recorded (lesion visible or not, discoloration visible or not). The
paratenon and lymph nodes were evaluated for abnormalities
of the thickness and color. Normal thickness and color were
differentiated from any other abnormalities. Any abnormality
found was recorded.
Histological sections were prepared from all formalin-fixed
samples and stained with haematoxylin & eosin (HE). All samples
were evaluated for presence of ectopic tissue and presence
of inflammation.
Samples of tendon and paratenon were scored according to
the general accepted semi-quantitative score system of Movin
et al. (35). Briefly, fiber structure, fiber arrangement, roundness of
the nuclei, regional variations in cellularity, vascularity, collagen
stainability, glycosaminoglycan content, and the presence of
inflammatory cells were evaluated by an experienced pathologist
(score 0: normal; score 1: slightly abnormal; score 2: moderately
abnormal; score 3: markedly abnormal).
Immunohistochemistry
Immunohistochemistry was performed to evaluate the
distribution percentage of collagen type I (COL I), collagen
type III (COL III), Von Willebrand Factor (VWF) and
smooth muscle actin (SMA). For each staining, 5µm thick
tendon sections were cut and mounted on Thermo Scientific
SuperFrost PlusTM adhesion slides (Fischer Scientific, UK).
Next, slides were deparaffinized and rehydrated in xylene and
decreasing concentrations of alcohol in H2O (96, 80, 70, 60,
and 100% H2O).
Collagen Type I
Antigen retrieval was performed by incubation with pronase
(1 mg/mL) and subsequently hyaluronidase (10 mg/mL) at
37◦C for 20min. Sections were treated with goat serum
[10% in phosphate-buffered saline (PBS)] for 15min at room
temperature, after which they were incubated with the primary
polyclonal rabbit collagen type I antibody (1:500; ab138492;
Abcam) for 60min at room temperature. Next, the secondary
anti-rabbit antibody (EnVision horseradish peroxidase (HRP)
anti-rabbit; K4001; Agilent) was incubated for 30min at room
temperature in the dark. Visualization was performed in
a 3.3-diaminobenzidine solution (DAB; K3468; Agilent) for
7min at room temperature in the dark. The cell nuclei were
counterstained with hematoxylin, after which the sections were
dehydrated and coverslips were applied. In between all steps,
the sections were washed extensively and repeatedly with 0.1%
PBS-Tween 20. Only after incubation with the secondary HRP
antibody, the slides were rinsed with PBS instead of 0.1% PBS-
Tween 20.
Collagen Type III
Antigen retrieval was performed using an EDTA buffer (10% in
distilled water; pH 9.0) for 30min at 95◦C. Next, slides were
incubated with H2O2 (S202386-2; Agilent) for 5min at room
temperature in the dark followed by a treatment with normal
goat serum (30% in PBS) for 30min at room temperature.
Subsequently, incubation with the primary polyclonal rabbit
collagen type III antibody (1:200; ab7778; Abcam) was performed
for 90min at room temperature followed by a secondary
incubation with anti-rabbit antibody (biotinylated anti-rabbit;
E0432; Agilent) for 30min at room temperature in the dark.
Next, incubation with ABC-HRP (Vector PK-6100) took place
for 30min in the dark at room temperature. Visualization was
performed in DAB as described above.
Von Willebrand Factor
Slides were incubated with proteinase K (0.05M in Tris-HCL, pH
7.6; S3004; Agilent) for 15min at room temperature for antigen
retrieval. Next, sections were incubated with H2O2 (S202386-
2; Agilent) for 5min followed by the primary polyclonal
rabbit VWF antibody (1:3200; A0082; Agilent) incubation for
30min at room temperature. Subsequently, the secondary anti-
rabbit antibody (EnVision HRP anti-rabbit; K4003; Agilent)
was incubated for 30min at room temperature in the dark.
Visualization was performed as described above.
Smooth Muscle Actin
Antigen retrieval was performed using a citrate buffer (10%
in distilled water; pH 6.0) for 13min in the microwave. Next,
sections were incubated with H2O2 (S202386-2; Agilent) for
5min followed by incubation with the primary monoclonal
mouse SMA antibody (1:200; M0851; Agilent) for 30min at
room temperature. Then, the secondary anti-mouse antibody
(EnVision HRP anti-rabbit; K4001; Agilent) was incubated for
30min at room temperature in the dark. Visualization was
performed as mentioned above.
Positive stainings were confirmed on microscopy. For
each section, a randomly selected area was photographed (at
×40 magnification). The percentage of the total stained area
(representing COL I, COL III, SMA, or VWF content) was
calculated with software (LAS, version 4.1, Leica microsystems,
Diegem, Belgium).
Data Analysis
All statistical analyses were performed using SAS R© statistical
analysis software version 9.3. The groups were compared to
baseline using ANOVA for the lameness assessment, increase
of tendon circumference and increase of local pain to pressure.
The treatment groups were compared using the Mantel-Haenszel
test for tendon assessment (pain, heat, and swelling), lameness
assessment, ultrasound assessment (echogenicity and fiber
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FIGURE 1 | Tendon assessment. (A) Local heat. 0 = no increase in temperature sensation; 1 = slightly increased temperature sensation; 2 = moderately increased
temperature sensation; 3 = severely increased temperature sensation. (B) Local pain to pressure. 0 = no pain to pressure; 1 = slight pain to pressure; 2 = moderate
pain to pressure; 3 = severe pain to pressure. (C) Local swelling. 0 = no swelling; 1 = slight swelling; 2 = moderate swelling; 3 = severe swelling. *P-values ≤ 0.05.
alignment score) and histopathology. Groups were compared
usingWilcoxon test for tendon circumference, anterior-posterior
thickness, UTC assessment and immunohistochemistry. Groups
were compared using the Fisher’s exact test for incidence of
adverse events, serious adverse events and suspected adverse
drug reactions, incidence of abnormal clinical signs and




Due to the study design each horse received the CP in one of
its forelimbs, whereas, the contralateral limb in each horse was
treated with the IVP.
Clinical Assessment
The clinical examination parameters, namely body temperature,
heart, and respiratory rates were all in the physiological range for
all horses at all time points. There was a mean increase of body
weight of 3.8 kg (± 4.05) from day−9 to day 111.
One adverse event was recorded: one horse showed mild signs
of colic 38 days following treatment. The horse also had reduced
feed intake the day after. No treatment was necessary and the
horse fully recovered. The condition was deemed not to be related
to the study medication.
No serious adverse events or suspected adverse drug reactions
were observed throughout the study period.
Hematological and Serum Biochemistry
Parameters
The analyses of the hematological and serum biochemistry
parameters revealed no serious deviations from the reference
values (Supplementary Material). The observed deviations were
marginally out of range and were regarded as not clinically
relevant by the attending veterinarian.
Tendon Assessment
Local Heat
There were no differences between the IVP group and the
CP group during the study period. Prior to surgery (day −9)
and from day 28 onwards, none of the horses showed increase
in local heat at the level of the SDFT area. On days 0–14 a
slightly increased temperature was observed in all limbs, with the
exception of day 4 where half of the limbs in each treatment group
showed no increased temperature (Figure 1A).
Pain to Pressure
There were no differences in pain to pressure between the IVP
and CP group. Prior to surgery (day−9) and from day 4 onwards,
none of the horses showed local pain to pressure. Between day 1
and 3, no or slight pain to pressure was observed in half of the
limbs in each treatment group (Figure 1B).
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Local Swelling
On day−9, 84, and 111 none of the horses showed local swelling.
On all other observation days, the scores ranged between 0 and
2. Significant differences between groups were seen on day 9
and 10, where the percentage of moderate swelling (score 2) was
significantly higher in the IVP group compared to the CP group
(P = 0.009 and P = 0.025, respectively) (Figure 1C).
No significant differences in tendon circumference could
be observed between groups throughout the study duration.
However, when changes of the mean tendon circumference
were compared to the baseline values of day 0 (after surgery,
but before treatment administration), a significant difference
between the IVP treated limbs and the contralateral CP treated
limbs could be determined on day 9 and 10 (P≤ 0.05). The mean
circumference of the CP group remained the same, whereas a
mean increase of 0.2 cm was observed in the IVP group when
compared to baseline.
FIGURE 2 | Lameness assessment. 0 = Lameness not perceptible under any
circumstances; 1 = Lameness is difficult to observe and is not consistently
apparent, regardless of circumstances; 2 = Lameness is difficult to observe at
a walk, or when trotting in a straight line, but consistently apparent under
certain circumstances; 3 = Lameness is consistently observable at a trot under
all circumstances; 4 = Lameness is obvious at a walk 5 = Lameness produces
minimal weight bearing in motion and/or at rest or a complete inability to move.
There was no significant difference in visual lameness scores
between the two treatment groups (IVP vs. CP). On days−9, 56,
and 111 none of the horses showed lameness (AAEP score 0). On
days 0 and 14, an AAEP lameness score of 1 was observed in both




There was no difference in echogenicity between the two
treatment groups from day −9 until day 28. From day 28
onwards, the frequency of scores indicating hypoechoicity (score
1–3) was significantly lower in the IVP treated limbs in
comparison to the CP treated limbs (P = 0.009 on day 28, P <
0.001 from day 42 to 84, P = 0.003 on day 111) (Figure 3A).
Fiber Alignment Score
There was no significant difference in fiber alignment score
between the two groups from day −9 until day 28. From day 28
onwards, the percentage of parallel fiber bundles was significantly
higher in the IVP group in comparison to the CP group (P <
0.001 at all time points) (Figure 3B).
No significant differences could be observed in anterior-
posterior thickness (APT) between both treatment groups from
day−9 until day 84. The increase in APT was significantly lower
of the IVP treated limbs compared to the CP treated limbs on day
84 (P = 0.010) and day 111 (P = 0.009) (Figure 4).
UTC Assessment
Echo type I (echo generated by intact and fully aligned fascicles,
green) was observed in the majority (82–84%) of the limbs in all
treatment groups on day −9 (before surgery). This percentage
dropped to 12–45% between day 0 and day 28. Significant
differences between groups were seen from day 42 onwards,
with significantly higher percentages for IVP treated limbs in
comparison to the CP treated limbs (P = 0.039 on day 42, P =
0.026 on day 56, P = 0.009 on day 84, and P = 0.007 on day 111)
(Figure 5A).
Percentage in echo type II (echo generated by discontinuous
and less aligned fascicles, blue) was not significantly different
FIGURE 3 | Ultrasound assessment. (A) Echogenicity scores: 0 = normal; 1 = mildly hypoechoic; 2 = moderately hypoechoic; 3 = severely hypoechoic. (B) Fiber
alignment scores: 0 = ≥ 75%; 1 = 50–74%; 2 = 25–49%; 3 = ≤ 24%. *P-values ≤ 0.05.
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between the two treatment groups at any observation day
(Figure 5B).
Echo type III (echo generated by a mainly fibrillar matrix, red)
was observed on day −9 in a relatively low percentage (3–5%)
of the limbs in all treatment groups, whereas this percentage
increased to 22–45% between day 0 and day 42. Significant
differences between groups were seen from day 56 onwards, with
lower percentages for IVP treated limbs when compared to the
CP treated limbs (P = 0.032 on day 56, P = 0.009 on day 84 and
P = 0.007 on day 111) (Figure 5C).
Echo type IV (echo generated by an amorphous matrix
and fluid, black) was observed on day −9 in a relatively low
percentage (6–7%) of the limbs in all treatment groups, whereas
this percentage increased to 11–44% between day 0 and day 56.
Significant differences between treatment groups were seen from
day 84 onwards, with lower percentages for IVP treated limbs in
comparison to the CP treated limbs (P = 0.026 on day 84 and P
= 0.021 on day 111) (Figure 5D).
On day 111, a significantly higher percentage in echo type I (P
= 0.008) and a significantly lower percentage in echo type III and
IV (P = 0.008 and P = 0.016 respectively) was observed in the
IVP treated limbs, as compared to day 0. No significant changes
in percentage of each echo type were observed in CP treated limbs
when compared to day 0.
Moreover, no significant differences could be observed in the
IVP treated limbs between day −9 and day 111 for any echo
type. This indicates that the tendon quality on day 111 after
intralesional tpMSC treatment is comparable with the healthy
tendon quality and structure as observed on day−9. This was not
the case for the CP treated limbs, where significantly lower echo
types I (P = 0.008) and significantly higher echo types III and IV




The lesion site was still visible in all SDFTs collected from both
treatment groups, as well as discoloration of the tendon tissue
(Figure 6). The thickness of the paratenon as well as the thickness
of the curial lymph nodes was considered to be normal in all
limbs of both groups.
Ectopic Tissue
No ectopic tissue was detected during histopathological
examination of the tendon, paratenon, or the cubital
lymph nodes.
Histologic Evaluation
In all organ and lymph node slides ectopic tissue and
inflammation were not observed.
Scoring of the Tendon Tissue
No significant differences of fiber structure, fiber arrangement,
roundness of the nuclei, regional variations in cellularity,
vascularity, collagen stainability, glycosaminoglycan content and
the presence of inflammatory cells could be observed between
treatment groups (Table 7).
FIGURE 4 | Mean (+SD) anterior-posterior thickness (cm). *P-values ≤ 0.05.
Immunohistochemistry
The results of percent distribution and immunohistochemical
stainings are depicted in Figures 7, 8, respectively.
Collagen Type I
The percent distribution of COL I was significantly higher for all
IVP treated limb in comparison to CP treated limbs (P = 0.005).
Collagen Type III
The percent distribution of COL III was significantly lower for all
IVP treated limb in comparison to CP treated limbs (P = 0.005).
Von Willebrand Factor
VWF was significantly higher for all IVP treated limbs in
comparison to CP treated limbs (P = 0.005).
Smooth Muscle Actin
The percent of distribution of SMA was significantly lower for all
IVP treated limb in comparison to CP treated limbs (P = 0.005).
DISCUSSION
This randomized, blinded and placebo-controlled study was
performed to evaluate the safety, tolerance, and efficacy of an
intralesional injection with allogeneic equine peripheral blood-
derived tenogenic primed mesenchymal stem cells (tpMSCs)
on surgically induced SDFT core lesions. The adapted surgical
procedure from Schramme et al. (31) was performed in the
SDFT of both forelimbs of each horse. This model provides
a more standardized and localized injury in comparison
with enzymatically induced lesions (36) and resembles the
naturally occurring injuries more closely in terms of clinical,
ultrasonographic, and histological findings (33, 37). The surgical
procedure induced a tendon lesion in both forelimb SDFT’s,
which could be confirmed by ultrasound and UTC assessment.
Because fibroplasia generally begins around the seventh day after
injury (29), the treatment was administered 1 week following
surgery, after the acute phase of the inflammatory response
caused by the surgical induction of the SDFT core lesion
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has subsided (38, 39). One forelimb of each horse received
an intralesional injection with tpMSCs and the contralateral
forelimb was treated with saline to serve as an intra-animal
control. This design allows to minimize the variability in
tendon quality between treatment groups, and the number of
experimental animals used (21, 33). This study design was similar
to a study by Bosch et al. (33) evaluating neovascularization
of tendon tissue after the surgical induction of a SDFT core
lesion. In that study evaluating six horses, one forelimb was
treated with platelet-rich-plasma (PRP) and the contralateral
limb with placebo (saline) to serve as an intra-animal control.
Increased neovascularization in the PRP treated limbs could
be demonstrated at 24 weeks post-injection, pointing out the
relevance of the current study protocol and the number of
horses used.
All eight treated horses were controlled for adverse events.
Only one adverse event, a colic episode at New Year’s Eve (38
days post-treatment), was observed in one horse, and the patient
fully recovered the next day without the need for treatment.
The adverse effect was not regarded to be related to the study
medication since the incidence in this study (1 episode in 1
out of 8 horses over 121 days of observation) is similar to the
incidence rate of colic in horses observed in the field (3.5–
10.6 cases per 100 horse years) (40). No other serious adverse
events or suspected drug reactions were observed throughout the
study period.
No significant difference between the tpMSC and contralateral
placebo treated limbs was observed for heat and pain to
pressure. Swelling was observed after surgery in all treatment
groups with similar distribution of scores. A significantly
higher swelling in the IVP treated limbs was recorded on
day 9 and 10, resulting in a higher tendon circumference in
comparison to baseline values. This reaction might be related
to the tpMSC treatment, however no other clinical signs
were associated. The swelling was limited (2mm), temporary
(2 days) and decreased from day 11 onwards. Comparable
studies also observed swelling following intra-lesional MSC
treatment, reporting a decrease from week 2 or week 8 after
MSC injection onwards using autologous BM-MSCs (41) and
AT-MSCs (23, 42).
FIGURE 5 | UTC assessment. (A) Mean (+SD) echo type I (green, fully aligned fascicles); (B) Mean (+SD) echo type II (blue, discontinuous and less aligned fascicles);
(C) Mean (+SD) echo type III (red, fibrillar matrix); (D) Mean (+SD) echo type IV (black, amorphous matrix and fluid). *P-values ≤ 0.05.
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FIGURE 6 | Macroscopic evaluation of the tendon tissue on day 112. (A)
Longitudinal and transverse sections of the control product treated forelimb.
(B) Longitudinal and transverse sections of the investigational product treated
forelimb.
TABLE 7 | Histological scoring of the tendon tissue.
Parameter IVP [mean (±SD)] CP [mean (±SD)]
Fiber structure 0.6 (0.9) 0.0 (0.0)
Fiber arrangement 0.6 (0.9) 0.1 (0.4)
Roundness of the nuclei 1.6 (0.9) 1.3 (0.5)
Regional variations in cellularity 1.6 (0.9) 1.9 (0.8)
Vascularity 1.8 (0.5) 1.4 (0.5)
Collagen stainability 2.1 (0.8) 1.6 (0.9)
Glycosaminoglycan content 2.8 (0.5) 2.4 (0.7)
Presence of inflammatory cells 0.6 (1.1) 0.5 (1.1)
Score 0, normal; score 1, slightly abnormal; score 2, moderately abnormal; score 3,
markedly abnormal.
Lameness (AAEP score 1) was observed on days 0 and 14 in
all forelimbs, but not at further lameness examinations. Within
the first and second week after an acute SDFT injury, mild
transient lameness can occur (43). Schramme et al. (31) reported
mild to moderate lameness in the 6-day period after surgical
induction of a bilateral SDFT core lesion. Within the following
2–7 days, lameness resolved rapidly. The observation of lameness
on days 0 and 14 is likely related to the surgical procedure and
is consistent with the clinical timeline observed with naturally
occurring tendon lesions.
Ultrasonography is the standard method to assess tendon
healing over time. Significant differences in fiber alignment score
and echogenicity between groups could be observed from day
28 onwards. The frequency of scores indicating hypoechoicity
and a relatively low percentage of parallel fiber bundles were
significantly lower in tpMSC treated limbs in comparison to
saline treated limbs. At the end of the study period, 7 out of
8 tpMSC treated limbs compared to 0 out of 8 control limbs
showed over 75% parallel fiber bundles in the lesion (score
0). Additionally, hypoechoic structures persisted significantly
longer in the placebo treated limbs compared to tpMSC treaded
forelimbs. This is in line with a previously performed study where
an improvement of the fiber alignment score was observed at
6 and 12 weeks after a combined tpMSC-PRP treatment (29).
Dyson et al. (5) demonstrated that the fiber alignment score
at 16 weeks can be correlated with the re-injury rate after 2
years. All horses with a fiber alignment score of 2 or 3 suffered
FIGURE 7 | Percentage distribution of COL I, COL III, VWF and SMA.
Comparison of mean distribution percentages (+SD) of extracellular matrix
proteins between investigation product treated limbs (IVP) and control product
treated limbs (CP). *P-values ≤ 0.05.
from a recurrent injury of the treated limb, whereas no horse
with a fiber alignment score of 0 re-injured the treated limb.
This might indicate that the significantly better results of the
tpMSC treatment in the current study in comparison to the
placebo treatment may lower the risk of re-injury in the long-
term. However, a field study should be performed in order to
confirm this hypothesis.
On the other hand, it has been shown that conventional
ultrasonography is not sufficiently sensitive to accurately and
unequivocally evaluate the composition of tendon tissue (44).
In a human study, a lower score for hypoechoicity was not
correlated with an improved clinical outcome (45). Therefore,
ultrasound tissue characterization (UTC) was included in the
present study to improve the objective tendon characterization
by standardizing instrumental settings. The UTC assessment
showed significant differences between groups from day 42
onwards for echo type I. The tpMSC treated limbs showed a
significantly higher echo type I percentage in comparison to the
placebo group. This echo type corresponds to healthy tendon
structure consisting of fully aligned intact tendon structures with
a high amount of collagen type I fibers (32). The percentages
of echo type III and echo type IV were significantly lower in
the tpMSC treated tendons in comparison to the placebo group
from day 56 to 84 onwards, respectively. Moreover, no significant
differences could be observed in the IVP treated limbs between
day −9 (before surgery) and day 111 for any echo type. This
indicates that the tendon quality on day 111 after intralesional
tpMSC treatment is comparable with the healthy tendon quality
and structure as observed on day−9.These findings demonstrate
that a more mature and superiorly healed tendon was present in
the tpMSC treated group at the end of the study compared to
the placebo group (32). The UTC results of the placebo group
reported by Bosch et al. (32) at 16 weeks post-injection are in
line with the placebo data of the current results 16 weeks after
treatment for types I and IV. This demonstrates that the model
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FIGURE 8 | Immunohistochemistry. Collagen type I in the (A) IVP and (B) CP treated limb, collagen type III in the (C) IVP and (D) CP treated limb, Von Willebrand
Factor in the (E) IVP and (F) CP treated limb and of smooth muscle actin in the (G) IVP and (H) CP treated limb. Scale bar = 10µm.
as well as the UTC scans were performed in a similar way.
However, when looking at PRP vs. tpMSC treatment considerable
differences could be noticed at the same time point between the
studies. Bosch et al. used a preliminary version of the tracker,
which was moved by hand along a magnetic strip (window size
9), rather than the automatic tracker used here. The results for
PRP in that study at week 16 showed much lower values of
echo type I compared to tpMSC treatment in our study (56 vs.
74%). Approximately the same percentages for all echo types
were reached at the end of the PRP study at week 24 as at week
16 in our study. This indicates a faster structural and functional
healing of the tendons treated with tpMSCs in comparison to the
PRP treatment.
The observations of the UTC assessment were confirmed by
the immunohistochemistry results obtained on day 112. The
high percentage of echo type I corresponding to healthy tendon
structure with a high amount of collagen type I fibers are in
line with the significantly higher distribution of collagen type
I in the tpMSC treated limbs compared to the placebo treated
limbs. Strength and elasticity of the tendon is provided by
collagen type I as the major fibrillar component. The presence
of a high amount of collagen type I is key for a functional,
high-quality healing of the tendon tissue and an important
indicator of tendon matrix synthesis (12, 21). In the placebo
treated limbs, more fibrotic tissue was observed as represented
by a higher percentage of echo type III on UTC and a higher
distribution of collagen type III and SMA and a lower amount
of blood vessels on immunohistochemistry. The SMA protein
is incorporated in myofibroblasts that play a role in early post-
inflammatory events after tendon injury (11). An increased
number of myofibroblasts results in the synthesis of abundant
amounts of COL III, resulting in the formation of persistent
scar tissue (46–48), reduced blood flow and eventually chronic
tendinopathies (49). The poor vascularization of tendons is
considered to be one of the reasons for their limited healing
potential (33). Blood vessels can be visualized by staining for
VWF, which can be found in functional endothelial cells and
thus acts as a marker for vascularization (50). The significantly
higher percentage of VWF in the tpMSC treated limbs in
the current study indicates a significantly enhanced healing
capacity in these limbs (33). In a similar study performed
by Conze et al. (50), where nine horses received AT-MSCs
in a surgically created SDFT lesion in one forelimb and a
placebo (inactivated autologous serum) in the contralateral
forelimb, an increased neovascularization of the AT-MSC treated
tendons was also observed at 22 weeks post-treatment. In
the present study no differences could be detected between
both treatment groups on histological sections, resulting in
an inconsistency with the UTC and immunohistochemistry
data. Although some studies could identify differences in
standard histopathological parameters (20, 51), other studies only
use immunohistochemistry instead of standard histopathology
to obtain objectively quantified results (33). The absence of
differences between the IVP and the CP treated tendons could
be due to the fact that only one section of tissue was imaged for
histological evaluation.
Another limitation of this study was including both forelimbs
making lameness harder to interpret, although only mild
lameness was observed during the study period without scoring
difficulties. Furthermore, the tpMSCs were not labeled so no
conclusions could be drawn in the matter of cell survival
and retention. Cell labeling was not performed to avoid
alterations of the final IVP that might influence the mode of
action. There was no biomechanical testing data or return to
exercise data to investigate the risk of re-injury. Additionally,
an experimental model was used to obtain standardized
circumstances. However, naturally occurring tendon injuries
present more variability and cannot always be treated on
the right time point in the healing process. Therefore, the
results of this study should be confirmed in a field trial on
a large number on horses suffering from naturally occurring
tendon disease.
This study demonstrates that allogeneic tpMSCs are well-
tolerated and may be effective in the management of tendon
injuries in horses. A higher percentage of intact and fully aligned
fascicles on UTC in the tpMSC treated limbs in comparison
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to placebo treated limbs demonstrate the beneficial effects of
tpMSCs for the treatment of tendon injuries in horses.
CONCLUSION
The administration of tenogenic primed mesenchymal stem cells
resulted in significantly higher amounts of intact and fully aligned
fascicles by UTC assessments and collagen type I distribution
by immunohistochemistry compared to a placebo treatment
after a single intralesional injection in surgically created SDFT
core lesions. Additionally, significantly improved echogenicity
scores and fiber alignment scores were recorded. Therefore,
equine allogeneic tpMSCs are a promising therapeutic for tendon
injuries in horses.
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